Lexmark acquires Claron to expand medical content

Lexmark International has acquired Toronto-based Claron Technology, a leading provider of medical image viewing, distribution, sharing and collaboration software technology. Lexmark paid a cash purchase price of approximately $37 million, which was funded entirely with Lexmark’s non U.S.-based cash, according to a release.

Claron’s solutions help healthcare delivery organizations provide universal access to patient imaging studies and other content across and between healthcare enterprises. One solution, a universal web-based zero-footprint viewer that enables diagnostic interpretation of medical images and related digital information on a variety of computers anytime, anywhere across a healthcare provider’s enterprise, supports viewing of all cleared DICOM imaging modalities and both 2D and 3D viewing while requiring no software to download while delivering a medical view comparable to any PACS solution.

“Digital content in all forms continues to exponentially grow, particularly in healthcare. Physicians, other providers and the health information exchanges must be equipped to utilize this content more quickly and collaborate more efficiently to better serve patients,” said Paul Rooke, Lexmark’s chairman and CEO. “The acquisition of Claron further differentiates Lexmark by providing solutions to help physicians and providers view images across devices and the enterprise, enabling better collaboration and patient care.”

Claron will report into Lexmark’s Perceptive Software. Claron and Lexmark’s other healthcare technology acquisitions are enabling Perceptive Software to further expand its medical content management strategy.

This acquisition follows Lexmark's strategy of pursuing acquisitions that support growth and increase software and solutions capabilities, while returning more than 50 percent of free cash flow to shareholders, on average, through quarterly dividends and share repurchases.

As part of this transaction, the surgical navigation portion of Claron will not transfer to Lexmark and will operate under the name Claronav.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.